BR112022014738A2 - Vetores à base de poxvírus produzidos por dna natural ou sintético e usos dos mesmos - Google Patents
Vetores à base de poxvírus produzidos por dna natural ou sintético e usos dos mesmosInfo
- Publication number
- BR112022014738A2 BR112022014738A2 BR112022014738A BR112022014738A BR112022014738A2 BR 112022014738 A2 BR112022014738 A2 BR 112022014738A2 BR 112022014738 A BR112022014738 A BR 112022014738A BR 112022014738 A BR112022014738 A BR 112022014738A BR 112022014738 A2 BR112022014738 A2 BR 112022014738A2
- Authority
- BR
- Brazil
- Prior art keywords
- poxvirus
- dna fragments
- based vectors
- natural
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
- C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969628P | 2020-02-03 | 2020-02-03 | |
| US202063113803P | 2020-11-13 | 2020-11-13 | |
| PCT/US2021/016247 WO2021158565A2 (en) | 2020-02-03 | 2021-02-02 | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014738A2 true BR112022014738A2 (pt) | 2022-10-11 |
Family
ID=77200801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014738A BR112022014738A2 (pt) | 2020-02-03 | 2021-02-02 | Vetores à base de poxvírus produzidos por dna natural ou sintético e usos dos mesmos |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4100514A4 (enExample) |
| JP (2) | JP2023512294A (enExample) |
| KR (1) | KR20220148823A (enExample) |
| CN (1) | CN115397998A (enExample) |
| AU (2) | AU2021217073A1 (enExample) |
| BR (1) | BR112022014738A2 (enExample) |
| CA (1) | CA3168836A1 (enExample) |
| IL (1) | IL294926A (enExample) |
| MX (1) | MX2022009200A (enExample) |
| WO (1) | WO2021158565A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| BR112023015467A2 (pt) | 2021-02-02 | 2023-10-10 | Geovax Inc | Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica |
| CN115433741A (zh) * | 2022-06-23 | 2022-12-06 | 广西大学 | 盖他病毒为载体表达报告蛋白的重组病毒的构建方法 |
| CN118240879A (zh) * | 2023-11-01 | 2024-06-25 | 上海市重大传染病和生物安全研究院 | 骨架质粒、重组质粒以及猴痘病毒颗粒和应用 |
| CN119506355B (zh) * | 2025-01-15 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 一种用于重组痘病毒包装的载体系统及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3099330A1 (en) * | 2018-05-02 | 2019-11-07 | Tonix Pharma Holdings Limited | Synthetic chimeric vaccinia virus |
-
2021
- 2021-02-02 CN CN202180025623.2A patent/CN115397998A/zh active Pending
- 2021-02-02 EP EP21750239.2A patent/EP4100514A4/en active Pending
- 2021-02-02 BR BR112022014738A patent/BR112022014738A2/pt unknown
- 2021-02-02 AU AU2021217073A patent/AU2021217073A1/en active Pending
- 2021-02-02 KR KR1020227030182A patent/KR20220148823A/ko active Pending
- 2021-02-02 MX MX2022009200A patent/MX2022009200A/es unknown
- 2021-02-02 JP JP2022547055A patent/JP2023512294A/ja active Pending
- 2021-02-02 WO PCT/US2021/016247 patent/WO2021158565A2/en not_active Ceased
- 2021-02-02 CA CA3168836A patent/CA3168836A1/en active Pending
- 2021-02-02 IL IL294926A patent/IL294926A/en unknown
-
2025
- 2025-12-24 AU AU2025287330A patent/AU2025287330A1/en active Pending
-
2026
- 2026-03-04 JP JP2026033811A patent/JP2026094336A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL294926A (en) | 2022-09-01 |
| WO2021158565A3 (en) | 2021-09-16 |
| JP2023512294A (ja) | 2023-03-24 |
| EP4100514A2 (en) | 2022-12-14 |
| WO2021158565A2 (en) | 2021-08-12 |
| EP4100514A4 (en) | 2024-06-12 |
| JP2026094336A (ja) | 2026-06-09 |
| CA3168836A1 (en) | 2021-08-12 |
| MX2022009200A (es) | 2023-01-04 |
| AU2021217073A1 (en) | 2022-08-18 |
| CN115397998A (zh) | 2022-11-25 |
| AU2025287330A1 (en) | 2026-01-22 |
| KR20220148823A (ko) | 2022-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009200A (es) | Vectores a base de poxvirus producidos por acido desoxirribonucleico (adn) natural o sintetico y usos de los mismos. | |
| BR112022023173A2 (pt) | Vacinas contra coronavírus com base na vacínia ankara (smva) modificada sintética | |
| BR112022018854A2 (pt) | Composições e métodos de rna circular | |
| PH12019501335A1 (en) | Thermostable cas9 nucleases | |
| BR112022023554A2 (pt) | Composições e métodos de rna circular | |
| MX2018012376A (es) | Sistemas de replicón de arterivirus recombinantes y usos de estos. | |
| BR112022013236A2 (pt) | Anticorpos anti-cd73 e usos dos mesmos | |
| BR112022014884A2 (pt) | Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave | |
| BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| AR112057A1 (es) | Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| MX2021014057A (es) | Polipéptidos de sintasas de cannabinoides optimizados. | |
| BR112021017603A2 (pt) | Vírus adenoassociado (aav) mutante tendo propriedade de direcionamento para o cérebro | |
| BR112015013004A2 (pt) | molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo | |
| AR067830A1 (es) | Proteinas streptococcus inmunogenicas | |
| RU2019112725A (ru) | Композиции и способы для повышения стабильности трансгенов в поксвирусах | |
| BR112023021587A2 (pt) | Fab anti-tslp com estabilidade melhorada, kit, composição, vetor, célula, método de produção e usos | |
| BR112019005516A2 (pt) | novo sítio de inserção do ehv orf70 | |
| BR112023003468A2 (pt) | Variantes de uma xiloglucanase da família 44 | |
| BR112021026484A2 (pt) | Polimerização de enzimas para reações de sequenciamento | |
| BRPI0504945A8 (pt) | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. | |
| MX2021002374A (es) | Metodos y composiciones para producir un virus. | |
| MX2018008797A (es) | Vacunas contra el cancer. |